Avedro, Inc.

Equities

AVDR

US05355N1090

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.61%	-.--%

2019	Avedro, Inc.(NasdaqGM:AVDR) dropped from S&P TMI Index	CI
2019	Avedro, Inc. Announces Board Changes	CI

Avedro, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019

November 06, 2019 at 09:04 am EST

Avedro, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced sales was USD 11.046 million compared to USD 8.018 million a year ago. Operating loss was USD 8.133 million compared to USD 5.139 million a year ago. Net loss was USD 9.065 million compared to USD 5.575 million a year ago. Basic loss per share was USD 0.52 compared to USD 3.96 a year ago. For the nine months, sales was USD 30.108 million compared to USD 19.467 million a year ago. Operating loss was USD 23.010 million compared to USD 16.577 million a year ago. Net loss was USD 24.846 million compared to USD 18.710 million a year ago. Basic loss per share was USD 1.74 compared to USD 13.42 a year ago.

Latest news about Avedro, Inc.

Avedro, Inc.(NasdaqGM:AVDR) dropped from S&P TMI Index	19-11-22	CI
Avedro, Inc. Announces Board Changes	19-11-21	CI
Avedro, Inc.(NasdaqGM:AVDR) dropped from NASDAQ Composite Index	19-11-21	CI
Glaukos Corporation completed the acquisition of Avedro, Inc. from a group of sellers.	19-11-20	CI
Avedro, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-06	CI
Certain Common Stock of Avedro, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2019.	19-08-12	CI
Certain Options of Avedro, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2019.	19-08-12	CI
Certain Warrants of Avedro, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2019.	19-08-12	CI
Certain Restricted Stock Units of Avedro, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2019.	19-08-12	CI
Avedro, Inc. Announces Resignation of Thomas W. Burns and Gilbert H. Kliman from the Board of Directors	19-08-07	CI
Avedro, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2019; Revises Revenue Guidance for the Full Year of Fiscal 2019	19-08-07	CI
Glaukos Corporation entered into a definitive merger agreement to acquire Avedro, Inc. from a group of sellers for approximately $490 million.	19-08-06	CI
Avedro, Inc.(NasdaqGM:AVDR) added to Russell 2000 Dynamic Index	19-06-28	CI
Avedro, Inc.(NasdaqGM:AVDR) added to S&P TMI Index	19-06-24	CI
Transcript : Avedro, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 05:15 PM	19-05-14
Transcript : Avedro, Inc., Q1 2019 Earnings Call, May 09, 2019	19-05-09
Avedro, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2019; Revises Revenue Guidance for the Full Year of Fiscal 2019	19-05-09	CI
Transcript : Avedro, Inc., Q4 2018 Earnings Call, Mar 21, 2019	19-03-21
Avedro, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2018; Provides Revenue Guidance for the Full Year of 2019	19-03-21	CI
Avedro, Inc.(NasdaqGM:AVDR) added to NASDAQ Composite Index	19-02-15	CI
Avedro, Inc. has completed an IPO in the amount of $70 million.	19-02-13	CI
Avedro, Inc. has filed an IPO in the amount of $86.25 million.	19-01-18	CI
Avedro To Seek Acquisition	19-01-18	CI
Avedro, Inc. Auditor Raises 'Going Concern' Doubt	18-12-20	CI
Avedro, Inc. Announces That Permanent J Code Issued for Avedro’S Photrexa® Drug Formulations	18-11-20	CI

Chart Avedro, Inc.

Duration

Period

More charts

Company Profile

Avedro Inc is a United States-based company. The Company is an ophthalmic pharmaceutical and medical device company developing and commercializing a suite of products based on its corneal collagen cross-linking technology platform to address a wide variety of ophthalmic disorders and conditions, primarily associated with corneal weakness. Its primary components of the Avedro Cross-Linking Platform are pharmaceutical formulations of riboflavin (vitamin B2), a âsingle dose pharmaceutical,â sold primarily in conjunction with the Companyâs innovative devices for the delivery of metered doses of ultraviolet (UVA) light, a medical device.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
AVEDRO, INC.	-.--%	403M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution